30.06.2013 Views

How does the operation of PHARMAC's 'Community Exceptional ...

How does the operation of PHARMAC's 'Community Exceptional ...

How does the operation of PHARMAC's 'Community Exceptional ...

SHOW MORE
SHOW LESS

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

for example value for money, equity or affordability. These values are described<br />

in <strong>the</strong> New Zealand Medicine Strategy (Minister <strong>of</strong> Health, 2007) as values<br />

which must be considered in decision making. This process eventually<br />

develops a lexicographical ordering <strong>of</strong> priorities based on each panel member’s<br />

preferred selections.<br />

Such frameworks require at some point <strong>the</strong> ranking <strong>of</strong> priorities <strong>of</strong> moral and<br />

ethical judgments. The research has demonstrated that approaches to carrying<br />

out such judgments are morally disputed. The data from <strong>the</strong> OIA requests to<br />

PHARMAC showed that doctors on <strong>the</strong> panels are <strong>the</strong>re to rule on clinical<br />

matters. PHARMAC <strong>does</strong> not explain how <strong>the</strong>se panellists are qualified (or<br />

entitled), more than any o<strong>the</strong>r citizen, to impress <strong>the</strong>ir own moral judgments on<br />

<strong>the</strong> outcomes <strong>of</strong> PHARMAC’s decisions. <strong>How</strong>ever, moral sensitivity and ethical<br />

reflection should be an integral part <strong>of</strong> <strong>the</strong> allocative decision making process<br />

(UNESCO, 2005). This is affected by <strong>the</strong> wider community, not just <strong>the</strong> expert<br />

medical practitioners chosen by PHARMAC to populate <strong>the</strong> various panels.<br />

Consequently, Gillon asserts that in <strong>the</strong> absence <strong>of</strong> a stated philosophical basis<br />

for PHARMAC’s decision making, Hansen’s system is undermined.<br />

Hadorn (2006) submitted to <strong>the</strong> Review <strong>of</strong> High-Cost Medicines that PHARMAC<br />

lacked <strong>the</strong> ability to introduce discussions about fairness into <strong>the</strong> decision<br />

making processes, particularly decisions about providing (or not providing)<br />

subsidies for high-cost medicines for individuals. He appealed to <strong>the</strong> distributive<br />

justice principles <strong>of</strong> Rawls and suggested that PHARMAC introduce a<br />

“Rawlsian Wrinkle” into <strong>the</strong> decision making process (Hadorn 2006). He<br />

described this wrinkle as aligned to Rawls’ difference principle, where <strong>the</strong><br />

needs <strong>of</strong> <strong>the</strong> least well <strong>of</strong>f are considered before <strong>the</strong> needs <strong>of</strong> <strong>the</strong> most well <strong>of</strong>f.<br />

This suggestion was not meant to undermine <strong>the</strong> clinical effectiveness or value<br />

for money assessments already carried out by PHARMAC. The wrinkle was<br />

suggested to add an assessment <strong>of</strong> fairness and equity into <strong>the</strong> wider utilitarian<br />

processes.<br />

239

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!